Suicide Risk in Placebo vs Active Treatment in Placebo-Controlled Trials for Schizophrenia

Abstract

Concern about increased risk of suicide or attempted suicide in the placebo group should not be an argument against the conduct of placebo-controlled trials in schizophrenia, provided that appropriate precautions are taken.